Juli 2022: I følge den nyeste forskningen utført av Emergen Research, nådde det globale markedet for CAR T-celleterapi en størrelse på 1.29 milliarder USD i 2021 og forventes å registrere en inntekts-CAGR på 24.9 prosent i løpet av prognoseperioden. Den økende forekomsten av kreft over hele verden, så vel som den økende dødeligheten forårsaket av kreft, forventes å være de viktigste driverne for inntektsvekst i det globale CAR-T-celleterapimarkedet i løpet av prognoseperioden. Utvidelsen av kliniske utprøvingsaktiviteter i et forrykende tempo, spredningen av fusjoner og oppkjøp, og lokket med offentlige tilbud er alle faktorer som bidrar til inntektsveksten i det globale CAR T-celleterapimarkedet.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global BIL T-celleterapi market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the BIL T-celleterapi market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Ytterligere viktige funn fra rapporten indikerer det
In 2021, the segment of diffuse large B-cell lymfom was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with kimær antigenreseptor T-celleterapi, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell non-Hodgkin lymfomer who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Nøkkelselskapene som for tiden opererer i markedet blir undersøkt videre i denne rapporten, i likhet med deres selskapsprofiler, produktporteføljer, ekspansjonsstrategier og strategiske allianser. Noen eksempler på denne typen allianser inkluderer fusjoner og oppkjøp, samarbeid og joint ventures. I tillegg til dette gir den høydepunkter om selskapets prestasjoner og økonomiske stilling, samt innsikt i markedsrekkevidden og den globale posisjonen til selskapet.
Selskaper profilert i det globale CAR T-Cell Therapy-markedet:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., og Eli Lilly and Company .
Les mer om den globale CAR T-Cell Therapy-markedsrapporten på: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
